Advertisement

Topics

Aeglea Biotherapeutics, Inc. Company Profile

06:40 EDT 19th September 2018 | BioPortfolio

Aeglea was founded in 2013 to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin.


News Articles [241 Associated News Articles listed on BioPortfolio]

Deals this week: Aeglea BioTherapeutics, BerGenBio, Evelo Biosciences

Aeglea BioTherapeutics intends to raise funds for its ongoing research and development (R&D), production and regulatory activities and other purposes....Read More... The post Deals this week: Aegl...

Aeglea BioTherapeutics Announces Positive Clinical Update

Aeglea BioTherapeutic issued an update on Tuesday for its ongoing Phase 1/2 trial of pegzilarginase in patients with a rare genetic disease, Arginase 1 Deficiency (ARG1-D). The post Aeglea BioTherapeu...

Aeglea BioTherapeutics Updates Phase I/II Trial Data

Aeglea BioTherapeutics announced new repeat dose data from its Phase I/II trial of AEB1102 (pegzilarginase) in patients with Arginase 1 Deficiency.

Aeglea nets $33.8mm via FOPO

Aeglea BioTherapeutics Inc. (enzyme therapies for rare genetic diseases and cancer) netted $33.8mm through the follow-on public offering of 4.5mm common shares at $8 each. The company will use some of...

Aeglea BioTherapeutics Announces Positive Clinical Updates

While some companies wait until clinical trials are finished with dosing and collecting data to begin releasing information, those that release interim data can give investors a better handle on how t...

Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase

Aeglea BioTherapeutics (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today a...

Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow

Aeglea BioTherapeutics (AGLE) Clinical Update Call - Slideshow

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]

Plasmanate [TALECRIS BIOTHERAPEUTICS, INC.]

Plasma Protein Fraction (Human) 5%, USPPlasmanate®

Gamastan s/d [TALECRIS BIOTHERAPEUTICS, INC.]

Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [25 Associated PubMed Articles listed on BioPortfolio]

Synthetic Biology and Engineered Live Biotherapeutics: Toward Increasing System Complexity.

Recent advances in synthetic biology and biological system engineering have allowed the design and construction of engineered live biotherapeutics targeting a range of human clinical applications. In ...

Cell Penetration Profiling Using the Chloroalkane Penetration Assay.

Biotherapeutics are a promising class of molecules in drug discovery, but they are often limited to extracellular targets due to their poor cell penetration. High-throughput cell penetration assays ar...

Integrated BioTherapeutics.

Live bacterial biotherapeutics in the clinic.

Glycosimilarity assessment of biotherapeutics 1: Quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept.

The carbohydrate moieties on the polypeptide chains in most glycoprotein based biotherapeutics and their biosimilars play essential roles in such major mechanisms of actions as antibody-dependent cell...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

This is a Phase 2, randomized, double-blind, placebo-controlled crossover study which will enroll up to 36 subjects (anticipated) with genetically confirmed mitochondrial disease who have ...

The Effect of OASIS Ultra on Critical Sized Wound Healing

The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. ...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [101 Associated Companies listed on BioPortfolio]

Aeglea Biotherapeutics, Inc.

Aeglea was founded in 2013 to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin.

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

Sephos Biotherapeutics

Sephos Biotherapeutics is a privately owned company focused on designing drugs for the treatment of cancer stem cells where the structure and biological activity of the drugs have...

Talecris Biotherapeutics Holdings Inc.

Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders i...

More Information about "Aeglea Biotherapeutics, Inc." on BioPortfolio

We have published hundreds of Aeglea Biotherapeutics, Inc. news stories on BioPortfolio along with dozens of Aeglea Biotherapeutics, Inc. Clinical Trials and PubMed Articles about Aeglea Biotherapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aeglea Biotherapeutics, Inc. Companies in our database. You can also find out about relevant Aeglea Biotherapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record